Market capitalization | $397.85m |
Enterprise Value | $322.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 5.30 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-67.05m |
Free Cash Flow (TTM) Free Cash Flow | $-62.21m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
11 Analysts have issued a aTyr Pharma, Inc. forecast:
11 Analysts have issued a aTyr Pharma, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -66 -66 |
14%
14%
|
EBIT (Operating Income) EBIT | -67 -67 |
14%
14%
|
Net Profit | -63 -63 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Sanjay Shukla |
Founded | 2005 |
Website | www.atyrpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.